<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01033240</url>
  </required_header>
  <id_info>
    <org_study_id>CS1008-A-U204</org_study_id>
    <nct_id>NCT01033240</nct_id>
  </id_info>
  <brief_title>CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer</brief_title>
  <official_title>Clinical Study Protocol Phase 2, Randomized Study of CS-1008 in Combination With Sorafenib Compared to Sorafenib Alone as First-Line Systemic Therapy in Subjects With Advanced Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and efficacy of CS-1008 in combination
      with sorafenib to sorafenib alone for treating liver cancer. Approximately 160 participants
      will take part in this study at approximately 22 sites (4 in the US, 8 in Japan, and 10 in
      Asia).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>time to progression (TTP) for chemotherapy naive subjects with advanced hepatocellular carcinoma (HCC)</measure>
    <time_frame>time to progression, up to 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>objective response rate (ORR) i.e. the proportion of subjects with the best response of complete response or partial response</measure>
    <time_frame>time to progression, up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>time to progression, up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">172</enrollment>
  <condition>Advanced Hepatocellular Carcinoma</condition>
  <condition>Liver Cancer</condition>
  <condition>Hepatic Cancer</condition>
  <condition>Liver Neoplasms</condition>
  <arm_group>
    <arm_group_label>Safety Cohort 1 CS-1008 and sorafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of CS-1008 and sorafenib; CS-1008 (2 mg/kg per week) in combination with sorafenib (400 mg self-administered by mouth [PO] twice daily [BID]) over 4 weeks observation, and may continue treatment until progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group 1 CS-1008 and sorafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of CS-1008 and sorafenib. Treatment Group 1: CS-1008 (6 mg/kg [or as determined] loading, 2 mg/kg/week maintenance) + sorafenib twice daily {BID} (N=50)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group 3 with sorafenib alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Combination of CS-1008 and sorafenib. Treatment Group 3: sorafenib BID (N=50)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Safety Cohort 2 CS-1008 and sorafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of CS-1008 and sorafenib; CS-1008 (4 mg/kg per week) in combination with sorafenib (400 mg self-administered by mouth [PO] twice daily [BID]) over 4 weeks observation, and may continue treatment until progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Safety Cohort 3 CS-1008 and sorafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of CS-1008 and sorafenib; CS-1008 (6 mg/kg per week) in combination with sorafenib (400 mg self-administered by mouth [PO] twice daily [BID]) over 4 weeks observation, and may continue treatment until progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group 2 with CS-1008 and sorafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of CS-1008 and sorafenib. Treatment Group 2: CS-1008 (6 mg/kg [or as determined] loading, 6 mg/kg/week [or maximum tolerated dose {MTD}] maintenance) + sorafenib BID (N=50)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CS-1008</intervention_name>
    <description>On a once a week basis CS-1008 will be administered intravenously starting at 2 mg/kg, followed by 4 mg/kg if tolerated, followed by 6 mg/kg if tolerated.</description>
    <arm_group_label>Safety Cohort 1 CS-1008 and sorafenib</arm_group_label>
    <arm_group_label>Treatment Group 1 CS-1008 and sorafenib</arm_group_label>
    <arm_group_label>Safety Cohort 2 CS-1008 and sorafenib</arm_group_label>
    <arm_group_label>Safety Cohort 3 CS-1008 and sorafenib</arm_group_label>
    <arm_group_label>Treatment Group 2 with CS-1008 and sorafenib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sorafenib</intervention_name>
    <description>On a daily basis, one sorafenib tablet, 400 mg, is taken orally twice a day. The total daily dose of sorafenib is 800 mg. The sorafenib tablets are taken at least 1 hour before or 2 hours after a meal.</description>
    <arm_group_label>Safety Cohort 1 CS-1008 and sorafenib</arm_group_label>
    <arm_group_label>Treatment Group 1 CS-1008 and sorafenib</arm_group_label>
    <arm_group_label>Treatment Group 3 with sorafenib alone</arm_group_label>
    <arm_group_label>Safety Cohort 2 CS-1008 and sorafenib</arm_group_label>
    <arm_group_label>Safety Cohort 3 CS-1008 and sorafenib</arm_group_label>
    <arm_group_label>Treatment Group 2 with CS-1008 and sorafenib</arm_group_label>
    <other_name>Nexavar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed HCC or clinical diagnosis of HCC when the
             following criteria are all met:

               -  History of chronic hepatitis and/or cirrhosis of liver;

               -  Typical features of HCC demonstrated in dynamic imaging studies, such as
                  three-phase computed tomography (CT); AND

               -  AFP level &gt; 200 ng/mL

          -  Advanced diseases

               -  Extrahepatic metastasis, OR

               -  Locally advanced diseases which are not amendable for surgical resection or other
                  loco-regional therapies including transhepatic arterial (chemo)embolization (TACE
                  or TAE) and local ablative therapy

          -  Measurable disease based on RECIST criteria (version 1.0) of at least 1 untreated
             target lesion that can be measured in 1 dimension

          -  At least 18 years of age

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

          -  Child-Pugh class A

          -  Life expectancy of at least 12 weeks

          -  Adequate organ and bone marrow function as assessed by clinical laboratory
             evaluations:

               -  Hemoglobin ≥ 8.5 g/dL (transfusion and/or growth factor support allowed)

               -  Absolute neutrophil count (ANC) ??? 1.0 x 109/L

               -  Platelet count ≥ 75 x 109/L

               -  Serum creatinine ≤ 1.5 x upper limit of normal (ULN) or creatinine clearance &gt; 40
                  mL/min

               -  AST and alkaline phosphatase ??? 5.0 x ULN

               -  Total bilirubin ≤ 1.5 x ULN

          -  Serum amylase and lipase ≤ 1.5 x ULN

          -  Women of childbearing potential must be willing to consent to using effective
             contraception (eg, abstinence, hormonal contraceptives, bilateral tubal ligation,
             barrier with spermicide, intrauterine device) while on treatment and for 3 months
             thereafter. Men who are the partner of a woman of childbearing potential must be
             willing to consent to using effective contraception (eg, vasectomy or barrier with
             spermicide) while on treatment and for 3 months thereafter

          -  All female subjects of childbearing potential must have a negative pregnancy test
             (serum or urine) result

          -  Subjects must be fully informed about their illness and the investigational nature of
             the study protocol (including foreseeable risks and possible side effects) and must
             sign and date an IRB/IEC approved ICF before performance of any study specific
             procedures or tests

          -  Subjects must be willing and able to comply with scheduled visits, treatment plan,
             laboratory tests, and other study procedures

        Exclusion Criteria:

          -  Any prior systemic therapy for HCC, including systemic chemotherapy (prior exposure to
             chemotherapy by TACE is allowed), immunotherapy, sorafenib or other Raf kinase
             inhibitors, VEGF/VEGFR-inhibitors, epidermal growth factor receptor inhibitors or mTOR
             inhibitors

          -  Radiotherapy or major surgical procedure within 4 weeks of the screening/baseline
             visit or minor surgical procedures (eg, core biopsy or fine needle aspiration) within
             2 weeks of the screening/baseline visit

          -  Anticipation of need for RT or a major surgical procedure during the study

          -  Any investigational agent within 4 weeks before the screening/baseline visit

          -  History of any of the following conditions within 6 months before the
             screening/baseline visit:

               -  Myocardial infarction with significant impairment of cardiac function (eg,
                  ejection fraction ≤ 30%)

               -  Severe/unstable angina pectoris

               -  New York Heart Association (NYHA) class III or IV congestive heart failure
                  (Section 17.2)

               -  Clinically significant pulmonary disease (eg, severe chronic obstructive
                  pulmonary disease or asthma)

          -  Clinically active brain metastases (defined as untreated, symptomatic or requiring
             steroids or anticonvulsants medications to control associated symptoms), uncontrolled
             seizure disorder; spinal cord compression; or carcinomatous meningitis. Subjects with
             treated brain metastasis will be included in the study if they have recovered from the
             acute, toxic effects of radiotherapy. A minimum of 15 days must have elapsed between
             the end of RT and the screening/baseline visit

          -  History of organ transplantation

          -  Clinically significant, severe, active infection requiring IV antibiotics

          -  Known history of human immunodeficiency virus (HIV) infection

          -  History of prior sensitivity reaction to any components of CS-1008 or sorafenib
             formulations

          -  History of a second malignancy, with the exception of in situ cervical cancer or
             adequately treated basal cell or squamous cell carcinoma of the skin

          -  Pregnant or breast feeding

          -  Serious intercurrent medical illnesses that, in the opinion of the Investigator, would
             impair the subject's ability to provide informed consent or unacceptably reduce the
             safety of the proposed treatment

          -  Clinically significant (National Cancer Institute Common Terminology Criteria for
             Adverse Events [NCI CTCAE] grade ≥ 3) gastrointestinal bleeding in the past 12 months
             or current active gastrointestinal bleeding

          -  Presence of esophageal varices at risk of bleeding, such as large esophageal/gastric
             varices or those with red sign, or active peptic ulcer with or without exposed vessels
             at risk of bleeding (as documented by endoscopy)

          -  History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess
             within past 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kenmar Research Group</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown-Lombardi Cancer Center</name>
      <address>
        <city>Washington DC</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kurume University Hospital</name>
      <address>
        <city>Kurume-shi</city>
        <state>Fukuoka</state>
        <zip>830-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hiroshima University</name>
      <address>
        <city>Hiroshima-city</city>
        <state>Hiroshima</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanazawa University</name>
      <address>
        <city>Kanazawa</city>
        <state>Ishikawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinki University Hospital</name>
      <address>
        <city>Osaka</city>
        <state>Osaka-sayama</state>
        <zip>589-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Med Center Cancer and Cardiovascular Disease</name>
      <address>
        <city>Higashinari-ku</city>
        <state>Osaka</state>
        <zip>537-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yamaguchi University Hospital</name>
      <address>
        <city>Ube</city>
        <state>Yamaguchi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiba University Hospital</name>
      <address>
        <city>Chiba</city>
        <zip>260-8677</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Okayama University Hospital</name>
      <address>
        <city>Okayama</city>
        <zip>700-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Musashino Red-Cross Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>180-8610</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Gangnam-gu</city>
        <state>Seoul</state>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>700-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>136-705</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catholic Univ. of Korea, Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital</name>
      <address>
        <city>Putz</city>
        <state>Chiayi</state>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohiung Chang Gung Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <state>Niaosung Hsiang</state>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chi-Mei Medical Center</name>
      <address>
        <city>Liouying</city>
        <state>Tainan County</state>
        <zip>736</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Changhua Christian Hospital</name>
      <address>
        <city>Changhua</city>
        <zip>500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohslung Medical University Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cheng-Kung University Hospital</name>
      <address>
        <city>Tainan city</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Medical Foundation-Linkuo</name>
      <address>
        <city>Taoyuan</city>
        <zip>33305</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2009</study_first_submitted>
  <study_first_submitted_qc>December 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2009</study_first_posted>
  <disposition_first_submitted>February 18, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>February 18, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 17, 2016</disposition_first_posted>
  <last_update_submitted>February 18, 2016</last_update_submitted>
  <last_update_submitted_qc>February 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

